Three generations of tyrosine kinase inhibitors (TKIs) for the EGFR were developed for the treatment of cancer patients, and the respective therapeutic molecules were grouped according to their structure or the target sites in the receptors [37]. The gene discussed is EGFR; the disease is cancer.